Radiotherapy and anthracyclines – cardiovascular toxicity

Dagmara Mozdzanowska; Marek Woźniewski

doi:10.5114/wo.2014.40108

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2015
vol. 19

Send email

Copy url:

abstract:

Review paper

Radiotherapy and anthracyclines – cardiovascular toxicity

Dagmara Mozdzanowska

,

Marek Woźniewski

Contemp Oncol (Pozn) 2015; 19 (2): 93–97

DOI: https://doi.org/10.5114/wo.2014.40108

Online publish date: 2014/06/24

View full text Get citation

PlumX metrics:

The subject of this paper is to analyze the impact of radiotherapy and anthracyclines on the cardiovascular system, based on a survey of contemporary literature. Currently, high efficiency of anticancer therapies has increased the rate of survival in patients treated for cancer. It should be emphasized, however, that these treatments damage not only the affected but also the healthy tissue. Consequently, with the increase of survival rate in these patients, the number of patients with complaints regarding numerous organs and systems also increases as a result of earlier treatment. Thus, during the first decade of the 21st century, a number of concerns about the relationship between cancer treatment and dysfunction of the cardiovascular system were resolved. Anthracyclines, as well as radiotherapy, are capable of damaging the cardiovascular system, both at the central level, by the deterioration of cardiac function, and at peripheral levels, by increasing the hemodynamic and thrombotic changes.

keywords:

Radiotherapy and anthracyclines – cardiovascular toxicity

Dagmara Mozdzanowska , Marek Woźniewski

radiotherapy, anthracyclines, chemotherapy, toxicity, cancer

Dagmara Mozdzanowska

,

Marek Woźniewski